Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

Plodkowski, Raymond A.; Nguyen, Quang Trinh; Sundaram, Umasankari; Nguyen, Loida; Chau, Diane; Jeor, Sachiko St.

doi:10.1517/14656560902775750

Cited by 45 publications

(27 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bupropion has numerous therapeutic indications including, depression [3], smoking cessation [4], sexual dysfunction [5], obesity [6], attention deficit hyperactivity disorder [7] and seasonal affective disorder [8]. It has recently been shown to have anti-inflammatory properties [9].…”

Section: Introductionmentioning

confidence: 99%

The aqueous stability of bupropion

O’Byrne

Williams

Walsh

et al. 2010

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The aqueous stability of bupropion

O’Byrne

Williams

Walsh

et al. 2010

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…Contrave is an experimental treatment for obesity in phase III clinical trials and is a combination of naltrexone and buproprion [40]. Each component has demonstrable efficacy as a weight loss agent.…”

Section: Combination Formulationsmentioning

confidence: 99%

Addiction Liability of Pharmacotherapeutic Interventions in Obesity

Greene

Sylvester²,

Joel³

2011

CPD

View full text Add to dashboard Cite

Obesity and substance use disorders are rapidly growing problems throughout the world. Of the current mainstay therapies of diet, exercise, behavioral modification, surgery, and medications, drugs have the greatest risk for abuse and dependence. As each of these disorders share similar underpinnings mediated by the dopaminergic brain reward pathways, clinicians must seriously consider the safety of both the patient's physical and mental health when prescribing treatments. Specifically, balance and awareness of the factors involved in the variable abuse potentials of these prescribed medications is paramount. A cursory review of weight loss medications commonly used is performed with attention to FDA status, mechanism of action, and abuse potential. Concurrent strategies to minimize risk such as drug screening, ruling out doctor shopping, temporal considerations, monitoring for signs and symptoms of abuse and/or dependency, and a safety-tiered prescribing approach is also discussed in order to optimize best treatment practice. As the understanding of these disorders progresses along with the evolution of agreed nomenclature and awareness of compulsive behavioral disorders in general, greater safety and more appropriate interventions may be achieved. Further areas of research will help to elucidate nuances of the coocurrance and treatment of these disorders and perhaps guide drug research and development in the area of drug treatments of obesity.

show abstract

“…One combination receiving special attention is the addition of naltrexone to bupropion, and several trials are ongoing [30].…”

Section: Bupropionmentioning

confidence: 99%

What are the risks and the benefits of current and emerging weight-loss medications?

Robinson¹,

Niswender

2009

Curr Diab Rep

View full text Add to dashboard Cite

Obesity is epidemic; new medications and therapeutic options are urgently needed to reduce the associated health care burden. The initial clinical strategy for weight loss is lifestyle modification involving a combination of diet, exercise, and behavior change. However, it is difficult for many to achieve and maintain weight loss solely through this approach. Only two drugs, orlistat and sibutramine, have been approved by the US Food and Drug Administration (FDA) to treat obesity long term, and both medications have undesirable side effects, leaving an enormous unmet need for efficacious and safe therapy for obesity. Other medications with weight-loss effects have been approved by the FDA for short-term treatment of obesity or for disorders other than obesity, but these also have potential adverse effects. This article discusses the perceived benefits and risks of these approved medications along with emerging drugs that have shown weight-loss effects.

show abstract

Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity

Cited by 45 publications

References 24 publications

The aqueous stability of bupropion

The aqueous stability of bupropion

Addiction Liability of Pharmacotherapeutic Interventions in Obesity

What are the risks and the benefits of current and emerging weight-loss medications?

Contact Info

Product

Resources

About